Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice

AIDS

Volumn 19, Issue 5, 2005, Pages 487-494

  Phillips, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiretroviral therapy; Resistance; Virological failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; UNITED KINGDOM; VIRUS LOAD;

EID: 17144369901     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000162337.58557.3d     Document Type: Article

References (13)

1. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-2388.
2. Scott P, Arnold E, Evans B, Pozniak A, Moyle G, Shahmenesh M, White D, Shirley J, Cane P, Pillay D. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chem 2004; 53 (3):469-473.
3. Kagan R, Winters M, Merigan T, Heseltine P. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res. Hum Retr 2004; 20 (1):1-9.
4. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
5. Miller MD, Margot NA, McColl DJ, Coakley DF. Characterization of virological failure through 96 weeks among treatment naïve patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz. In: 2nd International AIDS Society Conference. Paris, 2003 [Abstract 553].
6. UK Collaborative HIV Cohort (UK CHIC) Steering Committee. The creation of a large UK-based multicantre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine 2004; 5:115-124.
7. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS Society-USA panel. Clin Infect Dis 2003; 37 (1):113-128.
8. nd Edition. Blackwell Science; 2003.
9. Phillips AN Miller V, Sabin C, Lepri AC, Klauke S, Bickel M, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15 (18):2379-2384.
10. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18 (4):651-655.
11. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189 (1):51-60.
12. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Meyer WA, Klingman K, et al. ACTG: 5095 A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. N Engl J Med 2003; 350:1850-1861.
13. Harrigan PR, Dong W, Yip B, Wynhoven B, Woodward J, Mo T, Hogg R, Montaner J. Comprehensive longitudinal evaluation of HIV drug resistance in a large cohort starting initial HAART therapy in British Colombia, Canada. In: 2nd International AIDS Society Conference. Paris, 2003 [Abstract 829].